197 related articles for article (PubMed ID: 23223053)
1. A need for speed: Signals in drug development.
Nat Med; 2012 Dec; 18(12):1730-1. PubMed ID: 23223053
[No Abstract] [Full Text] [Related]
2. Breakthrough programme turns two.
Mullard A
Nat Rev Drug Discov; 2014 Dec; 13(12):873-5. PubMed ID: 25435204
[No Abstract] [Full Text] [Related]
3. Access before approval--a right to take experimental drugs?
Okie S
N Engl J Med; 2006 Aug; 355(5):437-40. PubMed ID: 16885545
[No Abstract] [Full Text] [Related]
4. 2013 FDA drug approvals.
Mullard A
Nat Rev Drug Discov; 2014 Feb; 13(2):85-9. PubMed ID: 24481294
[No Abstract] [Full Text] [Related]
5. Effective global drug development strategy for obtaining regulatory approval in Japan in the context of ethnicity-related drug response factors.
Ichimaru K; Toyoshima S; Uyama Y
Clin Pharmacol Ther; 2010 Mar; 87(3):362-6. PubMed ID: 20107436
[No Abstract] [Full Text] [Related]
6. Accelerated approval dust begins to settle.
Mullard A
Nat Rev Drug Discov; 2011 Oct; 10(11):797-8. PubMed ID: 22037027
[No Abstract] [Full Text] [Related]
7. The right to a trial: Should dying patients have access to experimental drugs?
Groopman J
New Yorker; 2006 Dec; ():40-7. PubMed ID: 17176539
[No Abstract] [Full Text] [Related]
8. Trends in risks associated with new drug development: success rates for investigational drugs.
DiMasi JA; Feldman L; Seckler A; Wilson A
Clin Pharmacol Ther; 2010 Mar; 87(3):272-7. PubMed ID: 20130567
[TBL] [Abstract][Full Text] [Related]
9. A long and winding road; evolution of antimicrobial drug development - crisis management.
Echols RM
Expert Rev Anti Infect Ther; 2012 Nov; 10(11):1311-9. PubMed ID: 23241188
[TBL] [Abstract][Full Text] [Related]
10. The Food and Drug Administration's early access and fast-track approval initiatives: how have they worked?
Shulman SR; Brown JS
Food Drug Law J; 1995; 50(4):503-31. PubMed ID: 10343017
[No Abstract] [Full Text] [Related]
11. Competitors try collaboration to speed drug development.
Patlak M
J Natl Cancer Inst; 2010 Jun; 102(12):841-3. PubMed ID: 20530762
[No Abstract] [Full Text] [Related]
12. Preclinical predictors of clinical safety: opportunities for improvement.
Sistare FD; DeGeorge JJ
Clin Pharmacol Ther; 2007 Aug; 82(2):210-4. PubMed ID: 17507920
[TBL] [Abstract][Full Text] [Related]
13. Drug development and FDA approval, 1938-2013.
Darrow JJ; Kesselheim AS
N Engl J Med; 2014 Jun; 370(26):e39. PubMed ID: 24963591
[No Abstract] [Full Text] [Related]
14. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
15. Cancer drug approval in the United States, Europe, and Japan.
Milsted RA
Adv Cancer Res; 2007; 96():371-91. PubMed ID: 17161686
[No Abstract] [Full Text] [Related]
16. [Current impact of natural products in the discovery of anticancer drugs].
Monneret C
Ann Pharm Fr; 2010 Jul; 68(4):218-32. PubMed ID: 20637355
[TBL] [Abstract][Full Text] [Related]
17. Two decades of new drug development for central nervous system disorders.
Kesselheim AS; Hwang TJ; Franklin JM
Nat Rev Drug Discov; 2015 Dec; 14(12):815-6. PubMed ID: 26585536
[No Abstract] [Full Text] [Related]
18. Toward molecular imaging-driven drug development in oncology.
de Vries EG; Oude Munnink TH; van Vugt MA; Nagengast WB
Cancer Discov; 2011 Jun; 1(1):25-8. PubMed ID: 22586317
[TBL] [Abstract][Full Text] [Related]
19. Learning from the 2012-2013 class of breakthrough therapies.
Mullard A
Nat Rev Drug Discov; 2013 Dec; 12(12):891-3. PubMed ID: 24287765
[No Abstract] [Full Text] [Related]
20. Discontinued drugs in 2010: cardiovascular drugs.
Zhao HP; Zhang XS; Xiang BR
Expert Opin Investig Drugs; 2011 Oct; 20(10):1311-25. PubMed ID: 21870899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
